| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1003028702 |
| P356 | DOI | 10.1023/A:1010954803886 |
| P698 | PubMed publication ID | 11469757 |
| P2093 | author name string | Espinel-Ingroff A | |
| Sheehan DJ | |||
| Boyle K | |||
| P2860 | cites work | In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi | Q28355507 |
| In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole | Q28369323 | ||
| In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi | Q28370628 | ||
| Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species | Q28379080 | ||
| In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species | Q28379197 | ||
| In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. | Q28379300 | ||
| In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp | Q28379320 | ||
| In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates | Q28379437 | ||
| In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection | Q28379496 | ||
| Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease | Q74593278 | ||
| In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species | Q77491810 | ||
| In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin | Q77713217 | ||
| Effects of voriconazole on Candida glabrata in vitro | Q30758598 | ||
| Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. | Q32122087 | ||
| Invasive aspergillosis caused by Aspergillus ustus: case report and review | Q33594021 | ||
| In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications | Q33676770 | ||
| Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates | Q33679210 | ||
| Organism-dependent fungicidal activities of azoles | Q33702101 | ||
| Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents. | Q33959480 | ||
| In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents | Q33959506 | ||
| In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. | Q33961573 | ||
| Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility | Q33962343 | ||
| Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species | Q33964175 | ||
| In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa | Q33975945 | ||
| In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. | Q33976969 | ||
| Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients | Q33977103 | ||
| Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans | Q33977302 | ||
| Correlation of fluconazole MICs with clinical outcome in cryptococcal infection | Q33979689 | ||
| In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum | Q33979873 | ||
| Amphotericin B: 30 years of clinical experience | Q34028160 | ||
| Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis | Q35134300 | ||
| In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. | Q35135265 | ||
| Itraconazole resistance in Aspergillus fumigatus | Q35136791 | ||
| In vitro evaluation of voriconazole against some clinically important fungi | Q35137870 | ||
| Trichosporon beigelii, an emerging pathogen resistant to amphotericin B | Q37186512 | ||
| In vitro activity of voriconazole against selected fungi | Q39233980 | ||
| Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens | Q39652421 | ||
| Resistant candidiasis. | Q40563228 | ||
| Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery | Q41001227 | ||
| International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections | Q41550505 | ||
| Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group. | Q41582315 | ||
| Disseminated Aspergillus ustus infection following cardiac surgery | Q44177954 | ||
| Lipid formulations of amphotericin B: clinical efficacy and toxicities | Q46460941 | ||
| High prevalence of antifungal resistance in Candida spp. from patients with AIDS. | Q47650748 | ||
| Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain. | Q54082831 | ||
| Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. | Q54091144 | ||
| In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. | Q54105202 | ||
| Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. | Q54125085 | ||
| National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. | Q54137486 | ||
| Candidiasis | Q58490233 | ||
| The Emerging Role of Fusarium Infections in Patients with Cancer | Q68297007 | ||
| In vitro activity of voriconazole against Candida species | Q74578695 | ||
| P433 | issue | 3 | |
| P921 | main subject | voriconazole | Q412236 |
| P1104 | number of pages | 15 | |
| P304 | page(s) | 101-115 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Mycopathologia | Q15763210 |
| P1476 | title | In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature | |
| P478 | volume | 150 |
| Q90049914 | A Review of Antimicrobial Therapy for Infectious Uveitis of the Posterior Segment |
| Q38476366 | A modified Christensen's urea and CLSI broth microdilution method for testing susceptibilities of six Malassezia species to voriconazole, itraconazole, and ketoconazole |
| Q39355795 | Activity of compounds isolated from Baccharis dracunculifolia D.C. (Asteraceae) against Paracoccidioides brasiliensis |
| Q40363459 | Administration of Voriconazole in Disseminated Talaromyces (Penicillium) Marneffei Infection: A Retrospective Study |
| Q42206400 | Advances in synthetic approach to and antifungal activity of triazoles |
| Q40799057 | Aggressive cutaneous zygomycosis caused by Apophysomyces variabilis in an immunocompetent child |
| Q39011788 | An Immunomodulatory Peptide Confers Protection in an Experimental Candidemia Murine Model |
| Q54394711 | An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. |
| Q42397163 | Antifungal activity of schinol and a new biphenyl compound isolated from Schinus terebinthifolius against the pathogenic fungus Paracoccidioides brasiliensis. |
| Q48065510 | Antifungal activity of trichothecenes from Fusarium sp. against clinical isolates of Paracoccidioides brasiliensis |
| Q34208354 | Antifungal agents: mechanisms of action |
| Q41906983 | Antifungal therapy in an athymic murine model of chromoblastomycosis by Fonsecaea pedrosoi |
| Q27028032 | Black yeasts and their filamentous relatives: principles of pathogenesis and host defense |
| Q91801347 | CNS Infections Caused by Brown-Black Fungi |
| Q31006560 | Cerebral phaeohyphomycosis caused by Fonsecaea monophora. |
| Q38553424 | Changes in Candida albicans colonization and morphology under influence of voriconazole |
| Q26796727 | Cladosporium keratitis - a case report and literature review |
| Q38609513 | Comparison of Neo-Sensitabs tablet diffusion assay with CLSI broth microdilution M38-A and disk diffusion methods for testing susceptibility of filamentous fungi with amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole |
| Q37636223 | Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. |
| Q35598532 | Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults |
| Q35598464 | Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults |
| Q40165489 | Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs |
| Q36738130 | Dematiaceous fungi |
| Q39228385 | Designing, synthesis, and antimicrobial action of oxazoline and thiazoline derivatives of fatty acid esters. |
| Q35757580 | Dual Invasive Infection with Phaeoacremonium parasiticum and Paraconiothyrium cyclothyrioides in a Renal Transplant Recipient: Case Report and Comprehensive Review of the Literature of Phaeoacremonium Phaeohyphomycosis |
| Q45192114 | Effect of voriconazole on a corneal abscess caused by fusarium |
| Q41868240 | Effectiveness of posaconazole in recalcitrant fungal keratitis resistant to conventional antifungal drugs. |
| Q50959184 | Effects of two 6-quinolinyl chalcones on the integrity of plasma membrane of Paracoccidioides brasiliensis. |
| Q40345252 | Efficacy of voriconazole in treatment of systemic scedosporiosis in neutropenic mice |
| Q90102308 | Eighty Years of Mycopathologia: A Retrospective Analysis of Progress Made in Understanding Human and Animal Fungal Pathogens |
| Q36607424 | Endogenous Candida endophthalmitis |
| Q36241012 | Endogenous endophthalmitis: diagnosis, management, and prognosis. |
| Q34747071 | Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans |
| Q35604935 | Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients |
| Q42596405 | Fusarium keratitis in Brazil: genotyping, in vitro susceptibilities, and clinical outcomes |
| Q36756216 | Fusarium keratitis: genotyping, in vitro susceptibility and clinical outcomes. |
| Q39743425 | Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei |
| Q37106292 | Genotypic identification of Fusarium species from ocular sources: comparison to morphologic classification and antifungal sensitivity testing (an AOS thesis). |
| Q44419424 | Headaches and hemiparesis in an immunocompetent inmate |
| Q33555655 | High-throughput identification and quantification of Candida species using high resolution derivative melt analysis of panfungal amplicons |
| Q99725688 | Histological Effects of Intravitreal Injection of Antifungal Agents in New Zealand White Rabbits: An Electron Microscopic and Immunohistochemical Study |
| Q35622011 | Human hyalohyphomycoses: a review of human infections due to Acremonium spp., Paecilomyces spp., Penicillium spp., and Scopulariopsis spp. |
| Q37132060 | Identification and Antifungal Susceptibility of Penicillium-Like Fungi from Clinical Samples in the United States |
| Q28476138 | Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay |
| Q34109559 | In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. |
| Q44126999 | In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study). |
| Q34749162 | In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. |
| Q38938057 | In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia |
| Q33859174 | In vitro activity of voriconazole against Prototheca wickerhamii: comparative evaluation of sensititre and NCCLS M27-A2 methods of detection |
| Q35870651 | In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection |
| Q57594600 | In vitro antifungal activity of fatty acid methyl esters of the seeds of Annona cornifolia A.St.-Hil. (Annonaceae) against pathogenic fungus Paracoccidioides brasiliensis |
| Q46656042 | In vitro antifungal activity of voriconazole against dermatophytes and superficial isolates of Scopulariopsis brevicaulis |
| Q57594588 | In vitro cytotoxic, antifungal, trypanocidal and leishmanicidal activities of acetogenins isolated from Annona cornifolia A. St. -Hil. (Annonaceae) |
| Q44930610 | In vitro fungitoxic activity of Larrea divaricata cav. extracts |
| Q34041745 | In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods |
| Q35879091 | In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods |
| Q51737787 | In vitro susceptibility of a large collection of Candida Strains against fluconazole and voriconazole by using the CLSI disk diffusion assay. |
| Q34327713 | Increased diversity of fungal flora in the vagina of patients with recurrent vaginal candidiasis and allergic rhinitis |
| Q35622021 | Infections caused by Fusarium species |
| Q40542583 | Infectious crystalline keratopathy caused by Cladosporium sp. after penetrating keratoplasty: a case report. |
| Q36558968 | Influence of different media, incubation times, and temperatures for determining the MICs of seven antifungal agents against Paracoccidioides brasiliensis by microdilution |
| Q40525637 | Influence of voriconazole and fluconazole on reconstituted multilayered oesophageal epithelium infected by Candida albicans |
| Q36018595 | Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults |
| Q46934279 | Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B. |
| Q36872848 | Invasive fungal infections and antifungal therapies in solid organ transplant recipients. |
| Q24633163 | Melanized Fungi in Human Disease |
| Q44111081 | Modest efficacy of voriconazole against murine infections by Sporothrix schenckii and lack of efficacy against Sporothrix brasiliensis |
| Q36242539 | Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. |
| Q42432176 | Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin |
| Q58404435 | New antifungal agents |
| Q44855715 | Newer antifungal agents |
| Q33981062 | Newer systemic antifungal agents : pharmacokinetics, safety and efficacy |
| Q34202213 | Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study |
| Q82798565 | Pan-azole-resistant Candida guilliermondii from a leukemia patient's silent funguria |
| Q36295392 | Penetration of amphotericin B lipid formulations into pleural effusion. |
| Q34719695 | Phaeoacremonium parasiticum infections confirmed by beta-tubulin sequence analysis of case isolates |
| Q34597632 | Pharmacokinetics and safety of intravitreal caspofungin |
| Q37641375 | Pharmacology and clinical use of voriconazole |
| Q46478249 | Pneumonia caused by Trichosporon pullulans in an autologous peripheral blood stem cell transplant recipient: possible misidentification |
| Q37409856 | Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations. |
| Q37420895 | Quality control limits for voriconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue |
| Q46710089 | Rapid identification of Candida tropicalis from canine cystitis |
| Q39767419 | Reflections on the approach to treatment of a mycologic disaster |
| Q46775309 | Retinal function assessed by ERG before and after induction of ocular aspergillosis and treatment by the anti-fungal, micafungin, in rabbits |
| Q34331049 | Safety of intravitreal voriconazole: electroretinographic and histopathologic studies |
| Q46976938 | Scedosporium apiospermum traumatic endophthalmitis successfully treated with voriconazole |
| Q35622016 | Scedosporium species infections and treatments |
| Q46849121 | Stability and in vitro activity of voriconazole eyedrops at a concentration of 3 microg/mL |
| Q86863318 | Stability of frozen 1% voriconazole ophthalmic solution |
| Q36891747 | Successful Outcome of DisseminatedFusariumInfection with Skin Localization Treated with Voriconazole and Amphotericin B-Lipid Complex in a Patient with Acute Leukemia |
| Q38917135 | Targeting CYP51 for drug design by the contributions of molecular modeling. |
| Q34195380 | Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study |
| Q36273788 | The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review |
| Q44863417 | The role of voriconazole in the treatment of emerging mycoses |
| Q36233517 | Therapy of infections caused by dematiaceous fungi |
| Q35787585 | Triazole Susceptibilities in Thermotolerant Fungal Isolates from Outdoor Air in the Seoul Capital Area in South Korea. |
| Q37892901 | Update on the optimal use of voriconazole for invasive fungal infections |
| Q44417870 | Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections |
| Q44564506 | Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients |
| Q35166823 | Voriconazole in the management of nosocomial invasive fungal infections |
| Q34045383 | Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients |
| Q40189236 | Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections |
| Q36164008 | Voriconazole: review of a broad spectrum triazole antifungal agent |
| Q37805648 | What do we know about Candida guilliermondii? A voyage throughout past and current literature about this emerging yeast |
Search more.